Terpene Rich Formulations For Symptom-Specific Care
Nicole Wicker, CEO, Altopa, and Al Shulman, CFO, ComCan Healthcare
The beneficial effects of CBD from hemp and THC from marijuana are well-documented and are recognized for their potential to address a variety of medical conditions. The roles of other cannabinoids such as CBG and CBN, and of terpenes derived from cannabis or from botanical sources, are not as well understood or documented. This presentation describes the use of specific combinations of cannabinoids and terpenes to address various medical conditions, the potential of personalized cannabis formulations in patient care, and clinical observations on the use of personalized formulations to address specific conditions.
Nicole is the CEO & co-founder of Altopa, maker of the Oblend. After discovering the medicinal powers of plant-based medicine, Nicole joined the cannabis industry to address the challenges that medicinal users face: lack of product consistency & personalization. Altopa’s proprietary device, the Oblend, solves these challenges by creating personalized, precise, consistent botanical formulations. Prior to Altopa, Nicole was CFO of TearScience, medical device company, where she raised a $45M Series C financing, followed by a $70M royalty financing. Under Nicole’s leadership, TearScience navigated through the FDA approval process and commercialized globally. Nicole was named NC’s CFO of the Year, and TearScience was awarded the fastest growing company during 2011, 2012 & 2013, followed by an acquisition by Johnson & Johnson. She has raised over $150 million for start-up and emerging growth companies. She has a consistent record of commercializing disruptive products, spurring rapid sales growth, and positioning companies for successful exits. Nicole spent over a decade with Ernst & Young as senior manager of the entrepreneurial services team and key player in multiple IPO and M&A transactions.
Al Schulman is CFO of ComCan Healthcare, the nation’s first Oblend Certified medical marijuana practice. Al spent more than 30 years as a Fortune 500 financial executive. He has a masters degree from the Sloan School of Management at MIT, and is a former adjunct professor of Finance at The Ohio State University.